Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from in vitro experiments, animal models and human studies. (PubMed, Front Immunol) - Sep 25, 2026 - "There are four S1P modulators currently approved by the Food and Drug Administration/European Medical Agency (FDA/EMA): fingolimod, siponimod, ponesimod, and ozanimod. Potential mechanisms underlying the observed effects involve selective modulation of S1P receptor subtypes (particularly S1PR1, S1PR3, and S1PR5). This comprehensive review summarizes available preclinical and clinical evidence on the role of S1P modulators in remyelination in the context of MS and shows that fingolimod, siponimod and ponesimod possess emerging promise in this field."
Journal • Preclinical • Review • CNS Disorders • Multiple Sclerosis • Solid Tumor • S1PR1 • S1PR5
|